AGN News and Press, Allergan plc From 08/30/19

DUBLIN , Aug. 30, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the Company and its U.S. subsidiaries have reached a settlement with plaintiffs scheduled for trial in October 2019 in the federal opioid multidistrict litigation. As part of the agreement, Allergan wil...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

Background for the Trade Merger arbitrage can generate above-market returns in a short time for those willing to bear the risk of the merger not closing. While over 80% of deals eventually close , the downside can be significant for the ones that don't. Those who engage in this strategy sho...

(Source: imgflip ) Recession risk is on the minds of many investors, and it's not hard to understand why. The Economic Policy Uncertainty Index, which tracks media reports of uncertainty (like inverted yield curve headlines) just hit an all-time high. This risks, according to Bank of Am...

AbbVie Inc (NYSE: ABBV) has been on a downward spiral since early 2018. Year to date, the company's share price has decreased by about 26%. This prolonged slump is unprecedented for AbbVie, at least since the firm spun off from Abbott Laboratories (NYSE: ABT) . Despite these headwinds,...

This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 08/14/2019. Please visit our Tracking David Tepper’s Appaloosa...

Quick Take Satsuma Pharmaceuticals ( STSA ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on the development of a treatment of acute migraine headache. STSA has begun Phase 3 trials and expects to pu...

Amgen (NASDAQ: AMGN ) and collaboration partner Allergan (NYSE: AGN ) announce  positive results from a second Phase 3 clinical trial, JASMINE , evaluating biosimilar candidate ABP 798 to the branded product, Roche's ( OTCQX:RHHBY ) Rituxan (rituximab) in patients with CD20-positive B...

THOUSAND OAKS, Calif. , Aug. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan ® (rituximab)...

AbbVie ( ABBV ) announced that it had received FDA approval for updatacitinib to be marketed as RINVOQ. It was approved to treat patients with rheumatoid arthritis. It is estimated that this drug alone for this indication could bring in multi-billion dollars for the company. This is good n...